FDA will convene the Pharmacy Compounding Advisory Committee (PCAC) on July 23-24, 2026, to discuss seven peptides for potential inclusion on the 503A bulks list. An additional five peptides will be ...
On March 20, 2024, the US Food & Drug Administration (FDA) issued a proposed rule titled Drug Products or Categories of Drug Products that Present Demonstrable Difficulties for Compounding Under ...
The US Food and Drug Administration (FDA) late Friday issued revised versions of two final guidance documents explaining the use of bulk drug substances in compounding and clarifying that the agency ...
HighlightsExecuted compounding agreement with a U.S.-based 503A sterile compounding pharmacy partnerCompounding activities ...
The FDA puts forward a move to exclude GLP-1 drugs from the bulk compounding list. Image credit: VICTOR TORRES/Stocksy According to the FDA’s announcement, the organization is asking for submitted ...
The U.S. Food and Drug Administration on Thursday proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a key compounding list, potentially limiting large-scale production by ...
In April, FDA detailed its priorities for drug compounding in 2019, which include issuing a new proposed rule to update the list of bulk drug substances that can be used in compounding under Section ...
Compounded semaglutide, tirzepatide and liraglutide could be harder to come by starting this summer, if the U.S. Food and Drug Administration (FDA) goes through with its plan to remove the three ...
Executed compounding agreement with a U.S.-based 503A sterile compounding pharmacy partner Compounding activities under the agreement expected to commence on Monday, June 1, 2026 All peptides under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results